Bayer showcased significant advancements in its pharmaceutical growth strategy and pipeline at its annual Pharma Media Day. As part of the ongoing transformation of its pharmaceutical business, Bayer has made significant investments in R&D to accelerate medical innovations and build a highly differentiated pipeline for long-term growth across key therapeutic areas, including oncology, cardiovascular diseases, neurology and rare diseases, and immunology. Bayer is also making significant progress